Simvastatin Tablets Recalled Due to Manufacturing Compliance Deviations
Preferred Pharmaceuticals is recalling Simvastatin Tablets, USP, 10 mg due to manufacturing compliance deviations identified at Accord Healthcare. No illnesses or injuries have been reported.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall involving manufacturing compliance deviations at the drug manufacturer. The hazard is manufacturing-related without specific health incidents reported; the score reflects risk-of-harm concern where injury has not yet been documented.
Plain-English summary
Simvastatin Tablets, USP, 10 mg in 90-count bottles (NDC 68788-9747-9) manufactured for Accord Healthcare, Inc., and distributed by Preferred Pharmaceuticals, Inc., are being recalled nationwide.
The recall was initiated following FDA inspection of Accord Healthcare's manufacturing facility, where current Good Manufacturing Practice (cGMP) deviations were identified. These manufacturing compliance deviations occurred at the facility responsible for producing this medication.
The recall affects 82 bottles with the following lot numbers and expiration dates: Lot C2222P, D1522L, E3122D, G2522J (expiration 9/30/2023) and Lot J1222R (expiration 10/31/2023). Patients currently taking this medication should contact their healthcare provider or pharmacist for guidance. No illnesses or injuries have been reported in connection with this recall.
The recalled product
- Product
- Simvastatin Tablets, USP, 10 mg, 90-count bottle, Rx only, Manufactured for: Accord Healthcare, lnc., Durham, NC 27703, NDC 68788-9747-9
- Manufacturer
- Preferred Pharmaceuticals, Inc.
- Hazard
- manufacturing-deviation
- cgmp-noncompliance
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot: C2222P
- D1522L
- E3122D
- G2522J
- Exp 9/30/2023
- Lot: J1222R
- Exp 10/31/2023.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27